Vera Therapeutics, Inc. Class A VERA 深 滬
等待開盤 02-07 09:30:00 美东时间
43.50
+2.550
+6.23%
華盛通- 最 高43.82
- 今 開41.90
- 成交量 103.92万股
- 最 低 41.32
- 昨 收 40.95
- 總市值 30.48亿
- 52周最高 56.05
- 市盈率 靜 --
- 換手率 1.48%
- 52周最低 18.53
- 委 比 -88.20%
- 總股本 7006.62万
- 歷史最高 56.05
- 量 比 0.98
- 振 幅 6.11%
- 歷史最低 5.20
- 每 手 1
- 風險率 9.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
Vera Therapeutics appointed Matt Skelton as Chief Commercial Officer to prepare for the commercial launch of atacicept, a potential treatment for IgA nephropathy. Skelton brings extensive experience in biotech commercialization and product launches. Atacicept, a dual BAFF/APRIL inhibitor, has shown promising clinical results in reducing proteinuria and stabilizing kidney function. Vera Therapeutics aims to transform treatments for serious immunol...
01-28 12:30
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics granted inducement awards, including stock options and RSUs, to 18 new employees under the 2024 Inducement Plan. Each stock option has an exercise price of $47.07, vesting over four years. RSU awards also vest over four years. Vera Therapeutics is a biotech company developing treatments for immunological diseases, with atacicept as its lead product candidate targeting autoimmune diseases like IgAN and lupus nephritis. The compan...
01-09 18:05
FDA Fast-Tracks Vera's At-Home Kidney Drug
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar market.
01-08 01:29
Vera Therapeutics Announces FDA Accepts Its Atacicept Biologics License Application For Priority Review To Treat Adults With Immunoglobulin A Nephropathy
Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the
01-07 20:33
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
Vera Therapeutics announced that the FDA has accepted the BLA for atacicept to treat IgAN, with a PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. The BLA was granted Priority Review and submitted under the Accelerated Approval Program. Atacicept received FDA Breakthrough Therapy Designation for IgAN and has shown significant reduction in proteinuria in cl...
01-07 12:30
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $96
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $99 to $96.
2025-12-20 00:31
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Vera Therapeutics announces $200M public offering
Vera Therapeutics (NVSDAQ:ERA) stated on Monday that it had commenced a public offering to issue and sell $200M of shares, and the underwriters will have a 30-day option to purchase up to an additiona...
2025-12-09 05:31
